Drug analysis: Cyramza

  • ID: 4462148
  • Drug Pipelines
  • 56 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Cyramza (ramucirumab; Eli Lilly/Shire) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature. The VEGF protein is an essential component of the angiogenesis pathway, which is critical for blood vessel formation, tumor growth, invasion, and metastasis. Cyramza inhibits tumor angiogenesis by preventing VEGF ligands VEGF-A, VEGF-C, and VEGF-D from binding to and activating the VEGFR-2 receptor, which in turn prevents the proliferation and migration of endothelial cells necessary for angiogenesis to occur. The lack of new blood vessels starves the tumors of their nutrient supply, resulting in tumor growth inhibition.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Cyramza: Colorectal cancer (CRC)
Cyramza: Hepatocellular carcinoma (HCC)
Cyramza: Bladder cancer
Cyramza: Non-small cell lung cancer (NSCLC)
Cyramza: Gastric cancer

List of Figures
Figure 1: Cyramza for colorectal cancer - SWOT analysis
Figure 2: Drug assessment summary of Cyramza for colorectal cancer
Figure 3: Drug assessment summary of Cyramza for colorectal cancer
Figure 4: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25
Figure 5: Cyramza for HCC - SWOT analysis
Figure 6: Drug assessment summary of Cyramza for hepatocellular carcinoma
Figure 7: Drug assessment summary of Cyramza for hepatocellular carcinoma
Figure 8: Cyramza for urothelial bladder cancer - SWOT analysis
Figure 9: Drug assessment summary for Cyramza in urothelial bladder cancer
Figure 10: Drug assessment summary for Cyramza in urothelial bladder cancer
Figure 11: Cyramza for non-small cell lung cancer - SWOT analysis
Figure 12: Drug assessment summary for Cyramza in non-small cell lung cancer
Figure 13: Drug assessment summary for Cyramza in non-small cell lung cancer
Figure 14: Cyramza for gastric cancer - SWOT analysis
Figure 15: Drug assessment summary for Cyramza in gastric cancer
Figure 16: Drug assessment summary for Cyramza in gastric cancer

List of Tables
Table 1: Cyramza drug profile
Table 2: Cyramza Phase III data in colorectal cancer
Table 3: Cyramza Phase I trials in colorectal cancer
Table 4: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 5: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016-25
Table 6: Cyramza drug profile
Table 7: Cyramza Phase III data in HCC
Table 8: Cyramza Phase III trial in HCC
Table 9: Cyramza Phase II data in HCC
Table 10: Cyramza drug profile
Table 11: Cyramza Phase III trial in urothelial bladder cancer
Table 12: Cyramza early-phase data in urothelial bladder cancer
Table 13: Cyramza drug profile
Table 14: Cyramza pivotal trial data in non-small cell lung cancer
Table 15: Cyramza ongoing late-phase clinical trials in non-small cell lung cancer
Table 16: Cyramza drug profile
Table 17: Cyramza pivotal trial data in gastric cancer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll